

- Gastrointestinal bleeding, 276
 approach to the patient, 278–279, 278f, 279f, 1885–1886
 aspirin-induced, 746
 in bleeding disorders, 404
 colonic diverticula and, 1891, 1893f
 in Crohn's disease, 1953
 diagnosis of, 278–279
 in Dieulafoy's lesion, 1891, 1891f
 differential diagnosis of, 1877t
 diverticular, 1971
 endoscopic evaluation of, 1885–1886
 from esophageal varices. *See* Esophageal varices
 in malabsorption syndromes, 1946t
 from Mallory-Weiss tears, 346e-1v, 1891, 1892f
 minor, endoscopic findings in, 1899, 1899f
 in peptic ulcer disease. *See* Peptic ulcer disease, complications of
 sources of
 colonic, 277, 1877. *See also* Hemorrhoidal disease; Rectal bleeding
 obscure, 279
 occult, 276, 279, 1896–1897, 1897f
 small intestinal, 277, 1877
 upper gastrointestinal, 276–277, 276t, 1877
 vascular ectasias and, 1891, 1892f
- Gastrointestinal cancer
 anal, 351, 543–544, 1198, 1199
 colorectal. *See* Colorectal cancer
 esophageal. *See* Esophageal cancer
 gastric. *See* Gastric adenocarcinoma
 gastric lymphoma, 535–536. *See also* Mucosa-associated lymphoid tissue (MALT) lymphoma
 gastric sarcoma, 536
 small bowel, 536–537
- Gastrointestinal disease, 1875. *See also specific diseases*
 approach to the patient, 1878–1879, 1879t. *See also* Gastrointestinal endoscopy
 classification of, 1875–1876
 clinical features of, 1876–1877, 1877t
 abdominal pain, 1877. *See also* Abdominal pain
 altered bowel habits, 1877. *See also* Constipation; Diarrhea
 ascites, 286
 gastrointestinal bleeding, 1877. *See also* Gastrointestinal bleeding
 heartburn, 1876
 involuntary weight loss, 275. *See also* Involuntary weight loss
 jaundice, 1877. *See also* Jaundice
 nausea and vomiting, 258, 1876–1877. *See also* Nausea and vomiting
 in diabetes mellitus, 2427
 genetic considerations in, 1876
 at high altitudes, 476e-4
 infections in cancer patient, 487–488
 in nerve agent exposure, 262e-5
 in pregnancy, 49
 in sepsis/septic shock, 1755
 in SLE, 2129t, 2131
 in sulfur mustard exposure, 262e-4
 in travelers. *See* Travelers' diarrhea
 treatment of, 98e-3, 1878–1879. *See also* Endoscopic therapy
- Gastrointestinal endoscopy, 1880. *See also specific types, e.g.,* Capsule endoscopy
 in anemia, 1896
 antibiotic prophylaxis for, 1884, 1888t
 antithrombotic drug management before, 1884, 1889t
 in Barrett's esophagus, 1881, 1882f, 1894–1895
 in biliary obstruction, 1885f, 1892
 in cancer staging, 1885f, 1900
 in celiac disease. *See* Celiac disease (gluten-induced enteropathy)
 in colonic pseudo-obstruction, 1892, 1894f
 for colorectal cancer screening. *See* Colonoscopy
 in diarrhea, 267, 1899
 in dyspepsia, 1894
 in dysphagia, 257, 1895–1896, 1896f
 in esophageal disease, 1901
 in gastric outlet obstruction, 1892, 1893f
 in gastrointestinal bleeding. *See* Gastrointestinal bleeding
 in gastrointestinal obstruction, 1891–1892, 1893–1894f
 in GERD, 1894, 1896f
 in hematochezia, 1899, 1899f
 indications for, 1878, 1879t
 in nausea and vomiting, 260
 in nonulcer dyspepsia, 1895
 open-access, 1900
 in pancreatitis, 1899–1900
 patient preparation for, 1900
 in peptic ulcer disease
 advantages of, 1919
 anesthesia for, 1881
 benign disease, 1919f
 duodenal ulcer, 1881f
 gastric ulcers, 1881f
 with hemorrhage, 1886, 1889f, 1890, 1890f
 procedure, 1881
 risks of, 1884
 therapeutic. *See* Endoscopic therapy
 upper tract, 262, 1881, 1881f, 1882f
 urgent, 1885
- Gastrointestinal hemorrhage. *See* Gastrointestinal bleeding
- Gastrointestinal motility test, 260
- Gastrointestinal neuroendocrine tumors (GI-NETs), 557. *See also* Pancreatic neuroendocrine tumors (pNETs)
 appendiceal, 561t, 563, 567
 carcinoid syndrome and. *See* Carcinoid syndrome
 cardiac manifestations of, 290e-1t, 290e-2–3, 1568
 classification of, 558, 560
 clinical features of, 268–269, 559t
 diagnosis of, 566, 2339
 gastric, 564
 general characteristics of, 557, 558t
 genetic syndromes associated with, 562, 562t
 hemoptysis in, 246
 incidence of, 559t, 560–561
 malignant behavior of, 559t, 560t, 561–562
 in MEN 1, 2336t, 2339
 metastatic, 269
 paraneoplastic syndromes in, 609t, 610, 619
 prognosis of, 561t, 573f
 rectal, 560t, 563, 567
 sites of, 537, 560, 560t
 small intestinal, 560t, 563, 567
 syndromes of, 559t. *See also* Carcinoid syndrome
 with systemic symptoms due to secreted products, 564
 treatment of, 567, 572–575, 2339
 tumor localization in, 571–572, 572f
 without carcinoid syndrome, 564
- Gastrointestinal obstruction. *See* Intestinal obstruction
- Gastrointestinal pseudoobstruction. *See* Intestinal pseudoobstruction
- Gastrointestinal stromal tumor (GIST)
 genetic considerations in, 102e-3, 119e-1
 metastatic, 119e-2
 pathology of, 119e-1
 treatment of
 angiogenesis inhibitors, 102e-17
 endoscopic resection, 346e-1v, 1886f
 imatinib, 102e-3, 536
 targeted chemotherapy, 102e-5t, 103e-19
- Gastrointestinal tract
 anaerobic flora of, 1094–1095, 1095t
 anatomy of, 1875
 extrinsic modulation of, 1875
 functions of, 1875
 microbiota in, 86e-7
 Gastrojejunostomy, 98e-8t
- Gastroparesis
 abdominal pain in, 262
 in chronic pancreatitis, 2101
 in diabetes mellitus, 2427
 diagnosis of, 263
 etiology of, 258
 indigestion in, 261, 262
 in mechanically ventilated patient, 1743
 nausea and vomiting in, 258
 in systemic sclerosis, 2161
 treatment of, 261, 1743
- Gastropathy, prolapse, 277
- Gastrostomy tube feeding, 98e-8t, 258
 GATA1 gene mutations, 135e-7, 729
 GATA2 deficiency, 420t, 2105–2106, 2105f
 GATA2 gene mutations, 670
 GATA4 gene mutations, 2354t
 GATA6 gene mutations, 2406
 Gatekeeper genes, 101e-5
 Gates Foundation, 8
 Gatifloxacin, 1115
 Gaucher cells, 432e-5
 Gaucher's disease, 432e-5
 cardiomyopathy in, 1565
 clinical features of, 432e-3t, 432e-5
 diagnosis of, 432e-5
 enzyme deficiency in, 432e-3t
 genetic considerations in, 432e-5
 myelofibrosis in, 672
 splenomegaly in, 411
 treatment of, 432e-5
 type 2, 432e-5
 type 3, 432e-5
- Gaze disorders
 horizontal, 209–210, 210f
 in MS, 2663
 supranuclear, 209
 vertical, 210
- Gaze stabilization reflex, 195
 GBA1 gene, 432e-5
 GBA gene mutations, 2612
 G-banding, 83e-1, 83e-1f, 83e-3t
 GBD 2010 (Global Burden of Diseases, Injuries, and Risk Factors Study 2010), 9
 GBS. *See* Guillain-Barré syndrome (GBS)
 GBS infections. *See* Group B *Streptococcus* (GBS) infections
 GB virus C (hepatitis G virus) infection, 1258
 GC regimen, for bladder cancer, 577
 G-CSF (granulocyte colony-stimulating factor), 372e-11t, 414f, 804
 G-CSF therapy. *See* Granulocyte colony-stimulating factor (G-CSF) therapy
 GDNF (glial-derived neurotrophic factor), 444e-7
- Gefitinib
 action and targets of, 103e-16, 103e-17t
 adverse effects of, 103e-16, 103e-17t, 380, 1797
 drug interactions of, 1793
 for head and neck cancer, 505
 for lung cancer, 102e-3, 102e-16, 520t, 521
 resistance to, 103e-23
- Gegenhalten (paratonia), 154
- Gemcitabine
 action of, 103e-14
 adverse effects of, 103e-11t, 103e-14, 577, 621, 1796, 1797, 1864
 for bladder cancer, 576, 577
 for breast cancer, 531
 for carcinoma of unknown primary, 120e-4
 for cholangiocarcinoma, 553
 for fibrolamellar hepatocellular carcinoma, 552
 for lung cancer, 519–520, 520t
 for ovarian cancer, 594
 for pancreatic cancer, 555, 556t, 557, 557t
 for soft tissue sarcoma, 119e-2
- Gemella morbillorum*, 821, 822t, 971
- Gemfibrozil
 adverse effects of, 2448t
 drug interactions of, 42t, 2199, 2449
 for hypertriglyceridemia, 2448t
 for metabolic syndrome, 2453